Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
IGC Pharma, Inc. (IGC)
Standardized SEC financial data for IGC Pharma, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001326205 · NYSE · Pharmaceutical Preparations.
Income statement
USD
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
$4.1M
$898K
$397K
$911K
$1.3M
$1.3M
Cost of revenue
$4.0M
$785K
$203K
$469K
$612K
$652K
Gross profit
$115K
$113K
$194K
$442K
$733K
$619K
R&D expense
$1.0M
$929K
$2.3M
$3.5M
$3.8M
$3.7M
SG&A expense
$6.0M
$7.9M
$13.3M
$8.6M
$6.8M
$4.4M
Operating income
-$6.9M
-$8.7M
-$15.4M
-$11.6M
-$9.8M
-$7.4M
EBITDA
-$6.7M
-$8.2M
-$14.8M
-$10.9M
-$9.2M
-$6.8M
Interest expense
$8K
$3K
$5K
$5K
$5K
$5K
Pretax income
-$7.3M
-$8.8M
-$15.0M
-$11.5M
-$13.0M
-$7.1M
Income tax
$0
$0
$0
$0
$0
$0
Net income
-$7.3M
-$8.8M
-$15.0M
-$11.5M
-$13.0M
-$7.1M
EPS (diluted)
—
—
—
—
$-0.22
$-0.09
Standardized from IGC Pharma, Inc.'s SEC filings — per-share figures split-adjusted. Full history via the API.